CCR4 and neoplasm: Mogamulizumab (KW-0761) is a defucosylated, humanized, IgG1 monoclonal antibody directed against CCR4 that has direct cytotoxic effect on CCR4-positive lymphoma cells via ADCC, as well as immunomodulatory potential by depletion of regulatory T cells to enhance anti-tumor immunity.